FTC sues to block GTCR’s $627M Surmodics acquisition
The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.
FTC challenges private equity firm’s acquisition of Surmodics
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq:SRDX) by GTCR.
FTC challenges $627M private equity takeover of Surmodics
The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition.”
US FTC sues to block private equity buy of medical company
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, saying the deal would contribute to high healthcare costs.
FTC sues to block Surmodics acquisition by private equity over device coating competition
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% of the hydrophilic coating market.
Surmodics says it will defend proposed acquisition by GTCR against FTC lawsuit
The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device coatings, is anticompetitive.” The acquisition of Surmodics by GTCR for $627 million was announced in May.
US FTC sues to block private equity purchase of medical company
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, saying the deal would contribute to high healthcare costs.
FTC sues to block acquisition of Surmodics
The Federal Trade Commission announced it has sued to block GTCR BC Holdings’ acquisition of Surmodics (SRDX), alleging that the deal, which
Surmodics drops after FTC files suit to block its planned sale to GTCR
Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale to private equity firm GTCR. The FTC filed suit in the U.S. District Court for the Northern District of Illinois,
Crain's Chicago Business1d
FTC targets GTCR in agency's first merger challenge under new Trump term
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Why Surmodics Stock Is Falling On Friday
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
News Medical4d
Microplates from BD Biosciences
BD was the first to offer a unique line of tissue culture vessels coated with a variety of extracellular matrix proteins and attachment factors: BD BioCoat™ cultureware. Today, BD continues to ...